Quantum Biopharma clinical trials we track

Check company identity source

Phase 2 1 trial

TrialDrugs studiedStatusPrimary completion
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)NCT05652907FSD201Terminated2023-05-24Actual

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Targeted treatment effect of 30% decrease from baseline to Day 28 in the average daily pain intensity. After: Measure: Targeted Treatment Effect of 30% Decrease From Baseline to Day 28 in the Average Daily Pain Intensity.

Check registry source